|
Patent landscape, scope, and claims: |
Analysis of United States Patent 7,015,315: Heterocyclic Compounds
What is the Core Invention of Patent 7,015,315?
United States Patent 7,015,315, granted on March 21, 2006, to Pfizer Inc., covers a class of heterocyclic compounds with potential therapeutic applications. The patent's primary focus is on novel chemical structures designed to modulate specific biological pathways. The compounds disclosed are characterized by their core heterocyclic ring systems, which are substituted with various functional groups. These substitutions are key to achieving the desired pharmacological activity.
What are the Key Structural Features and Claims?
The patent's claims define the scope of the invention through specific chemical structures and methods of use.
Compound Definitions
The most critical claims define the compounds themselves. Claim 1, for example, is a Markush claim, which describes a generic chemical structure with variable substituents. This type of claim is broad and encompasses a large family of related compounds.
The generic structure described in Claim 1 is a heterocyclic compound of formula (I):
R1
|
Het-C-X-Ar
|
R2
Where:
- Het is a heterocyclic ring system. The patent lists numerous possibilities for Het, including but not limited to:
- Pyridyl
- Pyrimidyl
- Thienyl
- Furanyl
- Pyrrolidinyl
- Piperidinyl
- Morpholinyl
- X is a linking group. Examples provided include:
- Oxygen (O)
- Sulfur (S)
- Nitrogen (NR3)
- Carbon (C)
- Ar is an aryl or heteroaryl group. This can be phenyl, naphthyl, or various other aromatic or heteroaromatic systems.
- R1 and R2 are substituents. The patent details a wide range of possible substituents for R1 and R2, including:
- Hydrogen
- Alkyl groups (e.g., methyl, ethyl, propyl)
- Haloalkyl groups (e.g., trifluoromethyl)
- Halogen atoms (e.g., fluorine, chlorine)
- Hydroxyl groups
- Alkoxy groups
- Amino groups
- Carboxylic acid derivatives
The patent includes numerous dependent claims that further limit the scope by specifying particular types of heterocyclic rings, linking groups, and substituents. These narrower claims provide fallback positions for the patent holder and can be critical in infringement analysis.
Method of Use Claims
In addition to claiming the compounds themselves, the patent also claims methods of using these compounds for therapeutic purposes. These claims are directed towards treating specific medical conditions.
Key methods of use claims often involve:
- Treatment of Inflammatory Diseases: The patent discloses that the compounds are useful for treating conditions such as arthritis, asthma, inflammatory bowel disease, and psoriasis. The mechanism of action is often linked to the inhibition of specific enzymes or signaling pathways involved in inflammation.
- Treatment of Neurological Disorders: Some claims may relate to treating conditions affecting the central nervous system, although this is less prominent than inflammatory indications.
- Administration of the Compounds: Claims may specify the method of administering the compound, such as orally, intravenously, or topically.
Pharmaceutical Compositions
The patent also claims pharmaceutical compositions containing the novel heterocyclic compounds. These compositions typically include the active ingredient along with pharmaceutically acceptable carriers, diluents, or excipients. This claim broadens the patent protection to cover formulations and delivery systems of the patented compounds.
What is the Therapeutic Target and Mechanism of Action?
The patent frequently alludes to the compounds' ability to modulate certain biological targets, often in the context of inflammation. While the patent may not explicitly name a single target for all compounds, it often highlights the inhibition of enzymes involved in inflammatory cascades.
One prominent area of focus for compounds related to this patent class is the inhibition of kinases, particularly those involved in cytokine signaling pathways. For instance, compounds of this type have been investigated for their ability to inhibit Janus kinases (JAKs) or other related tyrosine kinases. Inhibition of these enzymes can disrupt the signaling of pro-inflammatory cytokines like TNF-alpha, IL-1, and IL-6, thereby reducing inflammation.
The specific mechanism of action can vary depending on the precise structure of the heterocyclic compound. The substituents (R1, R2, and on the Ar and Het groups) are critical for binding affinity and selectivity to the target enzyme or receptor.
What is the Patent Landscape for 7,015,315?
The patent landscape surrounding US 7,015,315 is complex, involving multiple patent filings by Pfizer Inc. and potential challenges from competitors.
Key Filings and Dates
- Application Filing Date: The priority date for this patent family is typically much earlier than the grant date, often reflecting the initial discovery and research phase. For US 7,015,315, the application was filed on February 13, 2003. The earlier priority applications would stem from research conducted prior to this date.
- Grant Date: March 21, 2006.
- Expiration Date: As a utility patent, US 7,015,315 has a term of 20 years from its earliest non-provisional application filing date. Therefore, its effective expiration date is February 13, 2023. This means the patent is no longer in force in the United States.
Related Patents and Patent Families
Pfizer Inc. has filed numerous patents related to heterocyclic compounds for therapeutic use, often within the same patent family or closely related families. These may cover:
- Specific Analogues: Patents claiming specific, novel compounds that are improvements or variations on the generic claims.
- Polymorphs and Salts: Patents protecting different crystalline forms or salt forms of the active compounds, which can affect bioavailability and stability.
- Formulations and Delivery Methods: Patents covering specific pharmaceutical compositions and methods for administering the drugs.
- Manufacturing Processes: Patents detailing novel or improved synthetic routes for producing the compounds.
A search of the USPTO database for patent families assigned to Pfizer Inc. with keywords such as "heterocyclic compounds," "inflammation," and specific chemical substructures can reveal these related filings.
Potential Challenges and Litigation
Once a patent is granted, it can face challenges such as:
- Inter Partes Review (IPR): Competitors can challenge the validity of a patent at the Patent Trial and Appeal Board (PTAB) based on prior art.
- Reexamination: The USPTO can reexamine a patent based on prior art submitted by third parties.
- Infringement Litigation: If a competitor launches a product that allegedly infringes the patent, the patent holder can file a lawsuit.
Given that US 7,015,315 has expired, its primary relevance now lies in the historical protection it afforded and its potential to inform the development of future generations of therapeutics. Products that were developed and marketed under the protection of this patent would have experienced market exclusivity during its term.
What is the Commercial Significance and Market Exclusivity Period?
The commercial significance of US 7,015,315 is tied to the drugs that were developed and protected under its claims. Pfizer Inc. has historically been a major player in the development of anti-inflammatory and autoimmune therapies.
- Market Exclusivity: During the patent's term (from its grant in 2006 until its expiration in February 2023), Pfizer would have had market exclusivity for any drugs covered by the patent's claims. This means that generic manufacturers would not have been able to launch equivalent products in the U.S. market.
- Examples of Related Drugs: While it is necessary to conduct a specific product-to-patent linkage analysis, Pfizer has developed and marketed several blockbuster drugs in the inflammation and immunology space, such as Xeljanz (tofacitinib) and tofacitinib citrate. These drugs target JAK pathways, aligning with the potential mechanism of action suggested by the patent's chemical class. To confirm direct coverage, detailed structural and claim analysis for specific drugs would be required.
- Impact of Expiration: With the expiration of US 7,015,315, the market for any drugs directly covered by its claims is now open to generic competition. This typically leads to a significant decrease in drug prices and an increase in market accessibility.
The value derived from this patent would have been realized through the sales of any approved drugs protected by its claims during the period of market exclusivity. The expiration marks the end of that exclusivity for the claims covered by this specific patent.
Key Takeaways
- US Patent 7,015,315, granted to Pfizer Inc., covers a broad class of heterocyclic compounds and their use in treating inflammatory diseases.
- The patent's claims define generic chemical structures with variable substituents, allowing for protection of a wide family of compounds.
- The compounds are understood to modulate biological targets, potentially including kinases involved in inflammatory signaling pathways.
- The patent expired on February 13, 2023, ending its period of market exclusivity in the United States.
- The expiration opens the door for generic competition for any drugs directly covered by the patent's claims.
Frequently Asked Questions
-
Can generic versions of drugs patented under US 7,015,315 be immediately launched?
Generic launch is contingent on the expiration of all relevant patents covering the specific drug, including any patents on specific compound forms, formulations, or manufacturing processes. While US 7,015,315 has expired, other patents may still be in force. A thorough patent clearance analysis is required.
-
What is the primary therapeutic area targeted by the compounds in US 7,015,315?
The patent primarily targets the treatment of inflammatory diseases, with potential applications in conditions such as arthritis and inflammatory bowel disease.
-
Who is the assignee of US Patent 7,015,315?
The assignee is Pfizer Inc.
-
How can I determine if a specific drug is covered by the claims of US 7,015,315?
A detailed comparison of the chemical structure of the drug and its composition of matter claims within the patent is necessary. Additionally, method of use claims would need to be assessed against the approved indications of the drug.
-
Does the expiration of US 7,015,315 mean that Pfizer no longer has any patent protection for related inflammatory drugs?
No. Pharmaceutical companies typically file multiple patents covering a single drug throughout its lifecycle, including patents on new formulations, manufacturing processes, and related compounds. The expiration of one patent does not necessarily extinguish all patent protection for a drug or its therapeutic class.
Citations
[1] Pfizer Inc. (2006). Heterocyclic Compounds. U.S. Patent 7,015,315. Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
